As Kalil et al have recently evaluated [49], the strength of statistical and clinical evidence is weak for most clinical trials on therapies that have been recommended in recent guidelines for treating patients with severe sepsis, particularly for low dose steroids, recombinant human activated protein C, and early goal-directed therapy. This evidence concerns the gene PROC and Sepsis.